Clinical Trial

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-16; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT06512389
Lead Sponsor Centre for Addiction and Mental Health
Conditions Alcohol Use Disorder
Enrollment 36 participants
Start Date 2024-08-16
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20